Company Description

Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies.

It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPα blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis.

The company was founded in 2018 is based in LA Palma, California.

Liminatus Pharma, Inc.

Country	United States
Founded	2018
Industry	Biotechnology
Sector	Healthcare
CEO	Chris Kim

Contact Details

Address: 6 Centerpointe Drive, #625 La Palma, California 90623 United States
Phone	213 273 5453
Website	liminatuspharma.com

Stock Details

Ticker Symbol	LIMN
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001831874
ISIN Number	US53271X1081
SIC Code	6770

Key Executives

Name	Position
Chris Kim J.D., L.L.M.	Chief Executive Officer and Chairman
Scott Dam	Chief Financial Officer
Dr. Beom Kyu Choi	Chief Technology Officer and Member of Scientific Advisory Board
Dr. Byong Chul Yoo Ph.D.	Chief Science Officer and Member of Scientific Advisory Board
Dr. Sang-jin Lee Ph.D.	Head of Research and Development and Member of Scientific Advisory Board

Latest SEC Filings

Date	Type	Title
Apr 30, 2025	15-12G	Securities registration termination
Apr 16, 2025	10-K	Annual Report
Mar 31, 2025	NT 10-K	Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Mar 10, 2025	8-K	Current Report
Mar 5, 2025	25-NSE	Filing
Feb 7, 2025	DEFM14A	Filing
Jan 28, 2025	425	Filing
Jan 28, 2025	8-K	Current Report
Jan 16, 2025	425	Filing
Jan 16, 2025	8-K	Current Report

View All SEC Filings